ARTL earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -0.12. Updated 2026-07-23.
Artelo Biosciences (ARTL) Research Hub
Artelo Biosciences (ARTL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 5.43 USD (-9.20%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.12, market cap 0.00B. This hub links to the full technical, earnings and options research available for ARTL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 5.43 USD (-9.20%) |
| 52-week range | 5.34 USD – 12.15 USD |
| Trend regime | Range |
| 14-day RSI | 32.3 (Bearish) |
| Trailing P/E | -0.12 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for ARTL
Covered Call on ARTL: how it works, illustrative setup around the real 5.43 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ARTL: how it works, illustrative setup around the real 5.43 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ARTL: how it works, illustrative setup around the real 5.43 USD price, max profit/loss, breakeven and when to use it. Educational.
ARTL technical analysis: range, last 5.43 USD, RSI 32.3, 52w range 5.34 USD–12.15 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ARTL in?
Artelo Biosciences (ARTL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ARTL in an uptrend or downtrend?
As of 2026-09-11, ARTL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ARTL's trailing P/E ratio?
ARTL's trailing P/E is -0.12, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does ARTL next report earnings?
ARTL is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.72 USD.